Isabel Cuartas

Isabel Cuartas

Auto-generated profile, based on publicly available information

Isabel Cuartas

Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain. 1

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
RIRaffaella Iurlaro
Raffaella Iurlaro
IWInja Waldhauer
Inja Waldhauer
EPEster Planas-Rigol
Ester Planas-Rigol
EBEster Bonfill-Teixidor
Ester Bonfill-Teixidor
AAAlexandra Arias
Alexandra Arias
JSJoan Seoane
Joan Seoane
T-cell bispecific antibodies (TCB) are engineered molecules that bind both the T-cell receptor and tumor-specific antigens. Epidermal growth factor receptor variant III (EGFRvIII) mutation is a common event in glioblastoma (GBM) and is characterized by the deletion of exons 2–7, resulting in a constitutively active receptor that promotes cell proliferation, angiogenesis, and invasion. EGFRvIII is expressed on the surface of tumor cells and is not expressed in normal tissues, making EGFRvIII an ideal neoantigen target for TCBs. We designed and developed a novel 2+1 EGFRvIII-TCB with optimal pharmacologic characteristics and potent antitumor activity. EGFRvIII-TCB showed specificity for EGFRvIII and promoted tumor cell killing as well as T-cell activation and cytokine secretion only in patient-derived models expressing EGFRvIII. Moreover, EGFRvIII-TCB promoted T-cell recruitment into intracranial tumors. EGFRvIII-TCB induced tumor regression in GBM animal models, including humanized orthotopic GBM patient-derived xenograft models. Our results warrant the clinical testing of EGFRvIII-TCB for the treatment of EGFRvIII-expressing GBMs.

30 July 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EBEster Bonfill-Teixidor
Ester Bonfill-Teixidor
ANAlmudena Neva-Alejo
Almudena Neva-Alejo
AAAlexandra Arias
Alexandra Arias
ICIsabel Cuartas
Isabel Cuartas
RIRaffaella Iurlaro
Raffaella Iurlaro
JSJoan Seoane
Joan Seoane
Purpose: Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer. Experimental Design: We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment. Results: We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI. Conclusions: Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.

3 April 2023
Verified
Other
Open access
RIRaffaella Iurlaro
Raffaella Iurlaro
IWInja Waldhauer
Inja Waldhauer
EPEster Planas-Rigol
Ester Planas-Rigol
EBEster Bonfill-Teixidor
Ester Bonfill-Teixidor
AAAlexandra Arias
Alexandra Arias
JSJoan Seoane
Joan Seoane
Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma

1 October 2024
Verified
Other
Open access
EBEster Bonfill-Teixidor
Ester Bonfill-Teixidor
ANAlmudena Neva-Alejo
Almudena Neva-Alejo
AAAlexandra Arias
Alexandra Arias
ICIsabel Cuartas
Isabel Cuartas
RIRaffaella Iurlaro
Raffaella Iurlaro
JSJoan Seoane
Joan Seoane
Purpose:Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer.Experimental Design:We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment.Results:We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI.Conclusions:Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.

1 October 2024
Verified
Other
Open access
EBEster Bonfill-Teixidor
Ester Bonfill-Teixidor
ANAlmudena Neva-Alejo
Almudena Neva-Alejo
AAAlexandra Arias
Alexandra Arias
ICIsabel Cuartas
Isabel Cuartas
RIRaffaella Iurlaro
Raffaella Iurlaro
JSJoan Seoane
Joan Seoane
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Table S1, Supplementary methods

3 April 2023
Verified
Other
Open access
RIRaffaella Iurlaro
Raffaella Iurlaro
IWInja Waldhauer
Inja Waldhauer
EPEster Planas-Rigol
Ester Planas-Rigol
EBEster Bonfill-Teixidor
Ester Bonfill-Teixidor
AAAlexandra Arias
Alexandra Arias
JSJoan Seoane
Joan Seoane
Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma